Aryloxyacetic acids for diabetes and lipid disorders
AssigneeMerck & Co., Inc.
InventorsKun Liu, Libo Xu, A. Brian Jones
Life of this patent
Estimating the term…
Abstract
A class of aryloxyacetic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
Claims35
A compound having the formula I:
- 40
- and pharmaceutically acceptable salts and prodrugs thereof, wherein
- R1 and R2 are each independently selected from the group consisting of H, F, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-3 halogen atoms;
- or optionally R1 and R2 together form a C3-6 cycloalkyl;
- R3 and R4 are each independently selected from the group consisting of C1-C5 alkyl, C2-5 alkenyl, C2-5 alkynyl, and chlorine, provided that R3 and R4 are not both chlorine, wherein said alkyl, alkenyl, and alkynyl groups may be linear or branched and are optionally substituted with 1-5 fluorine atoms;
- X is N or CR;
- Y is O, S, or NR;
- Z is O or S;
- Each R is independently selected from the group consisting of H, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-5 fluorine atoms and/or one —OC1-3 alkyl, said —OC1-3 alkyl being optionally substituted with 1-7 fluorine atoms;
- and
- R5 is selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 Aryl, —OC1-6 alkyl, —OC2-6 alkenyl, —OC2-6 alkynyl, —OC6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, 5-6-membered Heteroaryl, —OC3-6 Cycloalkyl, —O 5-6-membered Heterocyclyl, —O 5-6 membered Heteroaryl, and a C1-4 alkyl group which comprises at a position interrupting the chain or at the end of the chain a group selected from C6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, and 5-6-membered Heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, —Oalkyl, —Oalkenyl, and —Oalkynyl is linear or branched and optionally substituted with 1-5 fluorine atoms and/or one —OCH3 or —OCF3 group, and each of said Aryl, Cycloalkyl, Heteroaryl, Heterocyclyl, —OAryl, —OCycloalkyl, —OHeteroaryl, and —OHeterocyclyl groups is optionally substituted with 1-7 halogen atoms and/or one —OCH3 or —OCF3 group.
A compound having Formula Ia
- 41
- and pharmaceutically acceptable salts thereof, wherein
- R1 and R2 are each independently selected from the group consisting of H, F, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-3 halogen atoms;
- or optionally R1 and R2 together form a C3-6 cycloalkyl;
- R3 and R4 are each independently selected from the group consisting of C1-C5 alkyl, C2-5 alkenyl, C2-5 alkynyl, and chlorine, provided that R3 and R4 are not both chlorine, wherein said alkyl, alkenyl, and alkynyl groups may be linear or branched and are optionally substituted with 1-5 fluorine atoms;
- X is N or CR;
- Y is O, S, or NR;
- Z is O or S;
- Each R is independently selected from the group consisting of H, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-5 fluorine atoms and/or one —OC1-3 alkyl, said —OC1-3 alkyl being optionally substituted with 1-7 fluorine atoms;
- R5 is selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 Aryl, —OC1-6 alkyl, —OC2-6 alkenyl, —OC6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, 5-6-membered Heteroaryl, —OC3-6 Cycloalkyl, —O 5-6-membered Heterocyclyl, —O 5-6 membered Heteroaryl, and a C1-4 alkyl group which comprises at a position interrupting the chain or at the end of the chain a group selected from C6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, and 5-6-membered Heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, —Oalkyl, —Oalkenyl, and —Oalkynyl is optionally substituted with 1-5 fluorine atoms and/or one —OCH3 or —OCF3 group, and each of said Aryl, Cycloalkyl, Heteroaryl, Heterocyclyl, —OAryl, —OCycloalkyl, —OHeteroaryl, and —OHeterocyclyl groups is optionally substituted with 1-7 halogen atoms and/or one —OCH3 or —OCF3 group;
- and
- R6 is a group that is easily removed under physiological conditions during or after administration to a mammalian patient to yield a compound having Formula I, or the carboxylate anion thereof (in solution), or a pharmaceutically acceptable salt thereof.
A compound having Formula Ia,
- 42
- and pharmaceutically acceptable salts thereof, wherein
- R1 and R2 are each independently selected from the group consisting of H, F, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-3 halogen atoms;
- or optionally R1 and R2 together form a C3-6 cycloalkyl;
- R3 and R4 are each independently selected from the group consisting of C1-C5 alkyl, C2-5 alkenyl, C2-5 alkynyl, and chlorine, provided that R3 and R4 are not both chlorine, wherein said alkyl, alkenyl, and alkynyl groups may be linear or branched and are optionally substituted with 1-5 fluorine atoms;
- X is N or CR;
- Y is O, S, or NR;
- Z is O or S;
- Each R is independently selected from the group consisting of H, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-5 fluorine atoms and/or one —OC1-3 alkyl, said —OC1-3 alkyl being optionally substituted with 1-7 fluorine atoms;
- R5 is selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 Aryl, —OC1-6 alkyl, —OC2-6 alkenyl, —OC6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, 5-6-membered Heteroaryl, —OC3-6 Cycloalkyl, —O 5-6-membered Heterocyclyl, —O 5-6 membered Heteroaryl, and a C1-4 alkyl group which comprises at a position interrupting the chain or at the end of the chain a group selected from C6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, and 5-6-membered Heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, —Oalkyl, —Oalkenyl, and —Oalkynyl is optionally substituted with 1-5 fluorine atoms and/or one —OCH3 or —OCF3 group, and each of said Aryl, Cycloalkyl, Heteroaryl, Heterocyclyl, —OAryl, —OCycloalkyl, —OHeteroaryl, and —OHeterocyclyl groups is optionally substituted with 1-7 halogen atoms and/or one —OCH3 or —OCF3 group;
- R6 is selected from the group consisting of —OR7, —OCH2OR7, —OCH(CH3)OR7, —OCH2OC(O)R7, —OCH(CH3)OC(O)R7, —OCH2OC(O)OR7, —OCH(CH3)OC(O)OR7, —NR8R8, and —ONR8R8;
- Each R7 is independently selected from C1-6 alkyl optionally substituted with one or two groups selected from —CO2H, —CONH2, —NH2, —OH, —OAc, NHAc, and phenyl;
- and
- Each R8 is independently selected from H and R7.
A compound represented by any of the structures of Examples 1-29, shown below:
- 2 Example 1 43 Example 2 44 Example 3 45 Example 4 46 Example 5 47 Example 6 48 Example 7 49 Example 8 50 51 Example R1 R2 R3 R4 R5 9 methyl methyl Cl propyl trifluoromethyl 10 ethyl H propyl propyl trifuoromethyl 11 ethyl methyl propyl propyl trifuoromethyl 12 propyl methyl propyl propyl trifluoromethyl 13 propyl H propyl propyl trifluoromethyl 14 propyl propyl propyl propyl trifluoromethyl 15 ethyl ethyl propyl propyl trifluoromethyl 16 methyl H Cl propyl ethyl 17 methyl methyl Cl propyl ethyl 18 methyl H Cl propyl trifluoromethyl 19 methyl methyl propyl propyl ethyl 20 methyl methyl propyl propyl methyl 21 methyl methyl propyl propyl methoxy 22 methyl H propyl propyl trifluoromethyl 23 methyl H propyl propyl phenyl 24 methyl methyl propyl propyl phenyl 25 methyl ethyl propyl propyl phenyl 26 H H propyl propyl trifluoromethyl 27 4-penten-1-yl H propyl propyl trifuoromethyl 28 cyclobutylidene propyl propyl trifuoromethyl 29 cyclohexylidene propyl propyl trifuoromethyl
Dependencies are inferred from the claim text.